

# VBC Release Highlights

January 27, 2023

Practice Insights<sup>SM</sup> is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).

## MIPS Quality Measures Dashboard

The MIPS Quality Measures Dashboard has been updated to reflect the below refinements for:

**NOTE:** Table continues on the next page.

Measure	Update	Practice Impact
<p>PIMSH 2: Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)</p>	<p>A refinement has been made to better attribute patients to the clinician most appropriate. The refinement requires a patient to have 2 qualifying E/M visits with a clinician during the measurement period to establish that the patient is under the clinician’s care. Numerator met will be attributed to the clinician who ordered the GCSF drug within 30 days of the patient receiving chemotherapy.</p>	<p>Practices may notice changes to the numerator and denominator due to the two E/M visit requirement not being met.</p>
<p>PIMSH 4: Patient-Reported Pain Improvement</p>	<p>A refinement has been made to the numerator criteria. For a patient who has an elevated pain score of 3 or greater, documentation of a decreased pain level within 30 days during a non-E/M visit will meet the numerator.</p> <p>A refinement has also been made to the denominator to exclude patients from the denominator who are on hormonal treatment only (i.e., not on active chemotherapy or radiation treatment).</p>	<p>Practices may notice an increase in the numerator and a decrease in the denominator due to this update. Removing patients receiving hormonal treatment from the denominator decreases the denominator.</p>

## Status of Dashboard Updates for 2022

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.

Measure	Description
<b>MIPS Quality Measures Dashboard</b>	
#047	Advance Care Plan
#104	Combination Androgen Deprivation Therapy for Prostate
#110	Preventive Care and Screening: Influenza Immunization
#128	Body Mass Index (BMI) Screening and Follow-Up Plan
#130	Current Medications Documentation
#134	Depression Screening
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
#236	Controlling High Blood Pressure
#374	Closing the Referral Loop
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#453	Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure)
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Metastatic Cancer

Measure	Description
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#12	COVID-19 Vaccinations
<b>OCM Performance Measures Dashboard 1H 2022</b>	
OCM 4A	Pain Intensity Quantified
OCM 4B	Plan of Care for Pain
OCM5	Depression Screening